Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Daina Graybosch’s rating is based on Gilead Sciences’ strong financial performance and promising pipeline developments. The company reported impressive third-quarter results, with both revenue and ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

Third Quarter 2024 Results Key Financial Results Revenue: US$7.55b (up 7.0% from ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

(Reuters) - Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...